Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 14, 2021, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg".
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 14, 2021, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg".